CAMBRIA-2

About this trial

Camizestrant (AZD9833) is an oral, potent, next-generation selective estrogen receptor degrader (ngSERD) and pure ER antagonist that has demonstrated significant anti-tumour activity and a favourable safety profile in patients with advanced breast cancer in the SERENA-1 and SERENA-2 studies.
The aim of this study is to assess if camizestrant results in improved invasive breast cancer-free survival (IBCFS) compared to standard adjuvant therapy in patients with ER+/HER2 early breast cancert with an intermediate-high or high risk of disease recurrence who have completed definitive locoregional therapy and have no evidence of disease. The currently approved endocrine therapy standard of care treatment is aromatase inhibitor or tamoxifen (with concurrent luteinising hormone-releasing hormone (LHRH) agonist added in pre- and peri-menopausal women and males) for 5 to 10 years.

Patient Profile

ER+/HER2- early breast cancer with intermediate-high or high risk of recurrence

Where’s this trial being run?

Beaumont Hospital, Cork University Hospital, St Vincents University Hospital, University Hospital Galway, University Hospital Waterford, Mater Misericordiae University Hospital, and Mater Private Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	CAMBRIA-2
Number:	23-06
Full Title:	CAMBRIA-2: A phase III, open-label, randomised study to assess the efficacy and safety of camizestrant (AZD9833, a next generation, oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or tamoxifen) as adjuvant treatment for patients with ER+/HER2- early breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence of disease.

Principal Investigator:	Prof Seamus O'Reilly
Type:	Industry Sponsored
Sponsor:	AstraZeneca
Recruitment Started:	Global: 5-Oct-2023 Ireland: 23-Dec-24

Global Recruitment Target:	5500
Ireland Recruitment Target:	140